Eaze Raises $25 Million in Total Funding

Life Science Investing News

Eaze, a private company focused on on-demand medical marijuana technology, announced the completion of a $13 million Series B financing round. The company has now raised more than $25M in total funding.

Eaze, a private company focused on on-demand medical marijuana technology, announced the completion of a $13 million Series B financing round. The company has now raised more than $25M in total funding.
As quoted in the press release:

Since launching in July 2014, Eaze technology has powered on-demand dispensary deliveries to hundreds of thousands of medical marijuana patients in nearly 100 California cities. Eaze technology connects patients with dispensaries, and provides logistics technology that enables dispensaries to deliver in less than 20 minutes. For patients in need of a medical marijuana recommendation, EazeMD connects California residents with board-certified doctors to receive an evaluation on demand through its mobile and online platforms.
“In an incredibly short period of time, Eaze has led the charge into an industry projected to grow from $7 billion this year to $50 billion by 2026,” said David Chao, general partner at DCM. “While many traditional VCs were reluctant to invest three years ago – Keith’s tech background and commitment to professionalism and compliance made the investment a no brainer. We invested in Eaze at the seed stage, preemptively led Series A, made a significant Series B investment, and will continue investing in Eaze as it continues to exceed our expectations.”

Click here for the full press release.

The Conversation (0)
×